inflection a our for you our critical critical morning, drivers. Judy. you, XXXX ANI, growth for X us taking was year everyone, Good Thank past for landmark points thank joining and call.
a successful and We medicines keep the best-in-class everything and need. our to and integration our further Purified Generics deliver XXXX launch Novitium, high-quality ANI business at of Our foundational of acquisition to The remain achievements organization. strengthen patient the do of significant asset, to to business the Rare of and Disease profitable generics deeply providing with committed patients R&D Cortrophin in Gel the growth. center sustainable, competitive we
full EBITDA I'm report surpassing revenues for over XXXX, that remarkable grew ANI XX% year-over-year. to company million, adjusted the in quarter, non-GAAP XXXX proud by million In fourth first the for company's the of in the history. an $XXX.X to for the quarter first was growth nearly time $XX.X year to from million a million, We This totaled $XXX revenues. record million in fourth quarter. $X.X delivered the mark revenues increase and million quarterly in the XX% $XXX $XX.X of
remain sustainable, need strategic turn Let to me X we profitable that and to now growth on competitive imperatives to drive in XXXX and the focused beyond.
is Rare our up The Disease business. first imperative scaling
foundational asset, has experienced momentum Our of year first great launch. through the Purified Gel Cortrophin
launch would expect, tweaks we our unfolded. the As strategy as you in made
of launch, We quarter the $XX.X sales our million, year total $XX.X for fourth pleased totaled are and that first were report million. sales to
Importantly, XXXX. has time first the class year-on-year according year-over-year IQVIA, gone growth for to ACTH therapy consistent the declines since of to unit from
year-on-year January has X ACTH XXXX, to seen consecutive of XXXX June the From category months growth.
As more with initiated of XXX cumulative than March than X, X,XXX cases more patient to increased new prescribers. unique
new alternate number in having to Overall, prescriber increasing an we and continued see unique have number of an continue repeat in in we that pleased of have interest prescribers treatment providers prescribers. becoming healthcare ACTH growth category to the the seen are build. We
chronic have targeted ACTH and Gel. the restarted Purified the autoimmune arthritis prescribers of to our Prescriptions excess multiple urinary includes distributed protein acute rheumatoid ACTH their use disorders, class Many nephrotic in slowed given of previously including Cortrophin the be discontinued continue certain launch or syndrome. sclerosis across of of our after had therapy exacerbations and use specialties, of which
key have Gel. awareness these understanding the physicians, participated We to actively have to also regional peer-to-peer specialties Cortrophin initiated and national in educate of and medical increase and programs across conferences
peer-to-peer education with have feedback. Our received programs positive been early well
We and have need. patients invested to and for across our with market expand are the PBMs payers access the and continuing appropriate commercial, Cortrophin efforts Medicaid in Medicare for
fulfillment. In our enhanced In reimbursement improve addition, to and XXXX, support reduce to of from we have Gel effectiveness enrollment services we patient these data time taken Cortrophin will augment increase and the several have we targeting. our access with experienced efforts initiatives sales to to further force. teams In taken parallel, the to strengthened highly prescriber
momentum on pulmonology. from sales focus we also modest to commence the our our will force launch, of With expansion
affairs, that Looking pharmacy Disease as we support, medical $XX a XXXX access Disease ANI shortly the in increase and to distribution. encompassing successfully actively company the We will leverage platform the the and or be has $XX Gel revenue a XX%. Cortrophin The believe patient scale confidence are expect asset, Cortrophin more Cortrophin we assets on business. Rare given partner exploring of specialty from ahead, foundational and built our and of at estimated to acquire discuss million the platform Rare success Gel market be Purified approximately to and SGA has Steve to in detail, range, to million
like business, I move important our Before would I point. to to an share Generics on
into of detailed launch, of days our and share we of to insight During investors progress metrics early believe it was launch. the the to give dynamics the important
prescribers as gathered initiated. metrics have confidence, momentum, number the sensitive Cortrophin we further of has launched have gained back cases pare and decided patient to detailed As competitively and investors such sharing
superior driving in limited-competition product products launched our excellence pharmaceutical our business supply new of imperative, execution, cost XX% and top generic to retained to ANDA reliability. a Sales XX strategic year-on-year. of and second growth new We ranking launch terms grew generics approvals. Generic now Moving several
compete of support given our Generics U.S. Generics XXXX, and investing market. continues R&D retain competitive that number generic expect second XX our to scale in ANDAs and a to especially business we growth This the therapy the ANI In aspirations. addition, continue to is large in In the for filed ranking of companies generics approvals. impressive
making also large the the is of at and speed our area operations excellence. manufacturing facilities The of are the Manufacturing in consolidation cost completed. Ontario on Oakville of products January to We XXXX track. Oakville network relocation been in site strides have U.S.
by We to potential discussions basis. once cash operational million buyers And efficiency profitability with executed, and are improve annualized $X is the in active million this Oakville site. on flow for an to expected fully $X GAAP
development need. our successful India. XX And Looking have serving contribute to we materially with analytical FDA and ahead, facility analytical The in audit the XXXX. ANI's over Chennai, and colleagues development at the -- patients completed sorry, a skilled today, in augmented to in FDA our facility efforts facility
ANI built reliable as Over and has a the to a reputation patients supplier customers. strong years,
goods. We and have invested in for both healthy finished maintaining materials inventory levels,
manufacturing chain the domestic a our supply U.S. enhances All supplier. are of in reliability and our our further as facilities
efforts high-quality during our practices compliance fourth the Most Finally, and FDA the quarter, strong in a recently, exemplifies conducted routine the audit to Minnesota. history at audit facilities Baudette, deliver manufacturing our facility medicines. our across good
I filled of needed business using million Baudette work our Indicated, proud inspection already report that corrective all with over We medicines. have received facility preventive EIR, our implemented actions the VAI. a or our Generics classifying dedicated prescriptions of ANI am establishment and XX have Voluntary employees favorable we is and Action and
taking our walk acquiring through or quarter Gel Disease Cortrophin of for forward a assets critical key discuss leverage year. guidance partnering on and a results In ANI's for the detailed momentum up building our the XXXX, growth, the landmark summary, coming points deal driver look that XXXX fourth past Rare Disease business. our for was ANI, to launch will on In us of inflection Steve financial now and scaling Rare we other Steve? our platform.
